Descrição
Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.
SEC Filing – Royalty Pharma
There's A Dark Cloud On Dropbox's Horizon
SEC Filing – Royalty Pharma
Lawrence Journal-World 06-18-2016 by Lawrence Journal-World - Issuu
Vertex trumpets data for new CF combo it hopes can outdo sluggish Orkambi
S-1
Long Zoom, Short WeWork: An Outrageous Profitable Idea (NYSE:WE)
Vertex casually drops Orkambi revenue slowdown, creating 'unnecessary drama' for investors
S-1/A
de
por adulto (o preço varia de acordo com o tamanho do grupo)
